NASDAQ:BVXV BiondVax Pharmaceuticals - BVXV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BiondVax Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $2.11 -0.06 (-2.76%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.10▼$2.1950-Day Range$2.10▼$3.0652-Week Range$2.03▼$19.65Volume10,698 shsAverage Volume25,777 shsMarket Capitalization$3.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BiondVax Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.30) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.23 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for BiondVax Pharmaceuticals. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.36% of the outstanding shares of BiondVax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBiondVax Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiondVax Pharmaceuticals has recently increased by 13.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiondVax Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiondVax Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BVXV. Previous Next 1.9 News and Social Media Coverage News SentimentBiondVax Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BiondVax Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BVXV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BiondVax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.03% of the stock of BiondVax Pharmaceuticals is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BiondVax Pharmaceuticals are expected to grow in the coming year, from ($0.30) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiondVax Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiondVax Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiondVax Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BiondVax Pharmaceuticals (NASDAQ:BVXV) StockBiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.Read More Receive BVXV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BVXV Stock News HeadlinesMarch 26, 2023 | marketwatch.comBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 VariantsMarch 25, 2023 | americanbankingnews.comBiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated by Analysts at StockNews.comMarch 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 19, 2023 | americanbankingnews.comBiondVax Pharmaceuticals (NASDAQ:BVXV) Earns Hold Rating from Analysts at StockNews.comMarch 16, 2023 | finance.yahoo.comBiondVax to Present at BIO-Europe SpringMarch 6, 2023 | finance.yahoo.comIBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir ReichmanMarch 3, 2023 | finance.yahoo.comIBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research InstitutesFebruary 2, 2023 | finance.yahoo.comBiondVax Presenting at BIO CEO & Investor ConferenceMarch 28, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...January 25, 2023 | benzinga.comBioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical StudyJanuary 25, 2023 | benzinga.comBiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19January 23, 2023 | markets.businessinsider.comBiondVax Pharma: In Vivo Data Shows NanoAb Virtually Prevents COVID-19 In HamstersJanuary 23, 2023 | finance.yahoo.comBiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment CandidateJanuary 23, 2023 | it.tmcnet.comBiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyJanuary 23, 2023 | finance.yahoo.comBiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyJanuary 15, 2023 | benzinga.comBioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical NeedsJanuary 6, 2023 | benzinga.comBiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyJanuary 6, 2023 | finance.yahoo.comBiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyJanuary 5, 2023 | finance.yahoo.comBiondVax to Present at Biotech Showcase 2023December 30, 2022 | finance.yahoo.comBiondVax CEO Issues Letter to ShareholdersDecember 21, 2022 | finance.yahoo.comAegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)December 16, 2022 | msn.comWhy Biondvax Pharmaceuticals Stock Is Getting Obliterated During Friday's Trading SessionDecember 13, 2022 | finanznachrichten.deBiondVax Pharmaceuticals Ltd.: BiondVax Regains Nasdaq ComplianceDecember 13, 2022 | finance.yahoo.comIBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.December 12, 2022 | finance.yahoo.comBiondVax Regains Nasdaq ComplianceDecember 8, 2022 | finance.yahoo.comBVXV: Positive Preclinical Results for Inhaled COVID-19 NanoAb…December 6, 2022 | finance.yahoo.comProfessor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory BoardSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BVXV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BVXV Company Calendar Last Earnings3/28/2022Today3/27/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BVXV CUSIPN/A CIK1611747 Webwww.biondvax.com Phone9723029302529Fax972-8930-2531Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-230.46% Return on Assets-35.35% Debt Debt-to-Equity Ratio5.92 Current Ratio5.76 Quick Ratio5.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.23 per share Price / Book0.40Miscellaneous Outstanding Shares1,870,000Free Float1,755,000Market Cap$3.95 million OptionableNot Optionable Beta2.49 Key ExecutivesAmir ReichmanChief Executive Officer & DirectorElad MarkChief Operating OfficerUri Ben-OrChief Financial OfficerTamar Ben-YedidiaChief Science OfficerDalit Weinstein FischerHead-Technical, Research & DevelopmentKey CompetitorsWindtree TherapeuticsNASDAQ:WINTPolarityTENASDAQ:PTEBrookline Capital AcquisitionNASDAQ:BCACKiromic BioPharmaNASDAQ:KRBPTC BiopharmNASDAQ:TCBPView All Competitors BVXV Stock - Frequently Asked Questions How have BVXV shares performed in 2023? BiondVax Pharmaceuticals' stock was trading at $2.96 on January 1st, 2023. Since then, BVXV shares have decreased by 28.7% and is now trading at $2.11. View the best growth stocks for 2023 here. When is BiondVax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our BVXV earnings forecast. How were BiondVax Pharmaceuticals' earnings last quarter? BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced its quarterly earnings data on Monday, March, 28th. The company reported ($2.70) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $1.80. When did BiondVax Pharmaceuticals' stock split? Shares of BiondVax Pharmaceuticals reverse split before market open on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of BiondVax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA). When did BiondVax Pharmaceuticals IPO? (BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO. What is BiondVax Pharmaceuticals' stock symbol? BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV." How do I buy shares of BiondVax Pharmaceuticals? Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BiondVax Pharmaceuticals' stock price today? One share of BVXV stock can currently be purchased for approximately $2.11. How much money does BiondVax Pharmaceuticals make? BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $3.95 million. The company earns $-12,850,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis. How can I contact BiondVax Pharmaceuticals? BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531. This page (NASDAQ:BVXV) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.